GET-73 is primarily researched for its potential therapeutic applications in the field of neuroscience and mental health. It is being studied as a potential treatment for alcohol use disorder (AUD) due to its interaction with the glutamatergic and GABAergic systems, which are crucial in regulating addictive behaviors. Early studies suggest that it may help reduce alcohol consumption and relapse by modulating neurotransmitter activity in the brain. Additionally, GET-73 is being explored for its potential neuroprotective effects, which could be beneficial in conditions involving neurodegeneration or cognitive impairment. Its ability to influence brain chemistry makes it a promising candidate for further development in treating substance abuse and related neurological disorders.